In this episode of Expose MASH [formerly NASH]—intended for US healthcare professionals only— we discuss the role that advanced practice providers (APPs) play in the screening and identification of patients with MASH (metabolic dysfunction-associated steatohepatitis). We explore their influence on patient care, their role in coordinating care, and discuss how their involvement in the MASH patient journey can impact patient outcomes. This episode is brought to you by Novo Nordisk Inc.

Overcoming Barriers to MASLD/MASH Screening in Clinical Practice

Recent advances in understanding steatotic liver disease have revealed overlapping biological processes that may contribute to non-alcoholic fatty liver disease (NAFLD). Join us in this podcast series where your colleagues will take you on a journey to better understand the cardiometabolic basis for metabolic dysfunction-associated steatohepatitis (MASH), formerly known as non-alcoholic steatohepatitis (NASH), which has long been recognized as “the hepatic manifestation of the metabolic syndrome.” In this series, we will explore MASH, including epidemiology, pathophysiology, comorbidities, patients at risk, and HCP perspectives on the patient journey. This series is tailored specifically for healthcare professionals seeking deeper insights into MASH.

Expose MASH [Formerly NASH] is tailored for healthcare professionals seeking to stay at the forefront of liver disease knowledge. This podcast is sponsored by Novo Nordisk and is intended for U.S. clinicians. This podcast is not to be used as medical advice.